FDA grants fast-track designation for Istesso’s IPF candidate
The therapy has reduced inflammation and supported the remodelling of damaged bone
Read More
Tag: IPF
NICE restricts NHS use of Roche’s IPF drug Esbriet
Cost regulators for NHS therapies in England and Wales have now issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF), but only in those with moderate to severe forms of the disease.
Read More
NICE refuses to expand use of Roche’s IPF drug Esbriet
The National Institute for Health and Care Excellence (NICE) it remaining steadfast in its position that Roche’s Esbriet should only be funded by the NHS for patients with moderate forms of the fatal lung scarring disease idiopathic pulmonary fibrosis (IPF).
Read More
BI unveils new data backing IPF drug Ofev
Two new analyses of data from late-stage trials of Boehringer Ingelheim’s lung drug Ofev presented at CHEST 2016 lend further weight to the body of evidence backing its effectiveness in people with idiopathic pulmonary fibrosis.
Read More
NICE says no to expanding scope of Roche’s IPF drug
Patients in England and Wales with the lung scarring disease idiopathic pulmonary fibrosis will have to wait until their disease has worsened before getting routine NHS access to Roche’s Esbriet.
Read More
DS Biopharma spins out Afimmune
Dublin, Ireland-based lipid science group DS Biopharma has launched a spin-out group focused solely on fibrotic conditions and pulmonary disorders.
Read More
Merck & Co to buy Afferent for up to $1.25 billion
Merck & Co is buying clinical-stage biotech Afferent Pharmaceuticals in a deal worth up to $1.25 billion.
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
